Abstract
328* Multicentre randomised double blind placebo controlled trial assessing the effect of weekly risedronate on bone mineral density in adults with cystic fibrosis C.S. Haworth1, L. Sharples2, V. Hughes3, S.L. Elkin4, M.E. Hodson5, S.P. Conway6, C. Etherington6, J.S. Elborn7, J. Rendall7, E. Wheaton2, E. Kadri8, J. Elliott1, H.C. Barker1, J. Compston9. 1Papworth Hospital, Adult Cystic Fibrosis Centre, Cambridge, United Kingdom; 2Institute of Public Health, MRC Biostatistics Unit, Cambridge, United Kingdom; 3Papworth Hospital, Research and Development, Cambridge, United Kingdom; 4St Mary’s Hospital, Respiratory Medicine, London, United Kingdom; 5Royal Brompton Hospital, Department of Cystic Fibrosis, London, United Kingdom; 6St James’s University Hospital, Cystic Fibrosis Centre, Leeds, United Kingdom; 7Belfast City Hospital, Adult Cystic Fibrosis Centre, Belfast, United Kingdom; 8Papworth Hospital, Pharmacy, Cambridge, United Kingdom; 9University of Cambridge, Department of Medicine, Cambridge, United Kingdom
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
